Geode Capital Management LLC Purchases 453,085 Shares of Heron Therapeutics, Inc. $HRTX

Geode Capital Management LLC raised its position in shares of Heron Therapeutics, Inc. (NASDAQ:HRTX) by 14.6% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 3,566,813 shares of the biotechnology company’s stock after acquiring an additional 453,085 shares during the period. Geode Capital Management LLC owned approximately 2.34% of Heron Therapeutics worth $7,385,000 as of its most recent SEC filing.

A number of other institutional investors have also made changes to their positions in the business. R Squared Ltd bought a new stake in Heron Therapeutics during the 2nd quarter valued at approximately $26,000. ProShare Advisors LLC raised its stake in Heron Therapeutics by 23.4% during the 2nd quarter. ProShare Advisors LLC now owns 31,368 shares of the biotechnology company’s stock valued at $65,000 after purchasing an additional 5,953 shares during the last quarter. Prospera Financial Services Inc acquired a new stake in Heron Therapeutics in the 2nd quarter worth $103,000. Deutsche Bank AG lifted its stake in shares of Heron Therapeutics by 43.2% in the first quarter. Deutsche Bank AG now owns 85,610 shares of the biotechnology company’s stock valued at $188,000 after buying an additional 25,824 shares during the period. Finally, Headlands Technologies LLC grew its position in Heron Therapeutics by 260.5% during the first quarter. Headlands Technologies LLC now owns 92,558 shares of the biotechnology company’s stock worth $204,000 after buying an additional 66,886 shares in the last quarter. 80.01% of the stock is currently owned by institutional investors.

Heron Therapeutics Stock Performance

Heron Therapeutics stock opened at $1.31 on Friday. The company has a market cap of $240.20 million, a PE ratio of -14.55 and a beta of 1.34. The company has a current ratio of 2.56, a quick ratio of 1.78 and a debt-to-equity ratio of 19.89. Heron Therapeutics, Inc. has a 1 year low of $1.00 and a 1 year high of $2.68. The company’s 50-day moving average is $1.20 and its two-hundred day moving average is $1.54.

Heron Therapeutics (NASDAQ:HRTX) last posted its quarterly earnings results on Tuesday, November 4th. The biotechnology company reported ($0.05) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.02) by ($0.03). The company had revenue of $38.21 million for the quarter, compared to analyst estimates of $39.03 million. Equities analysts anticipate that Heron Therapeutics, Inc. will post -0.13 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several analysts have recently weighed in on HRTX shares. Weiss Ratings reissued a “sell (e+)” rating on shares of Heron Therapeutics in a report on Wednesday, October 8th. Needham & Company LLC reduced their price objective on shares of Heron Therapeutics from $4.00 to $3.00 and set a “buy” rating for the company in a report on Friday, August 8th. Wall Street Zen lowered shares of Heron Therapeutics from a “buy” rating to a “hold” rating in a research report on Saturday, August 9th. Jefferies Financial Group restated a “buy” rating on shares of Heron Therapeutics in a research note on Tuesday, November 4th. Finally, Zacks Research upgraded Heron Therapeutics from a “strong sell” rating to a “hold” rating in a research report on Tuesday, October 7th. Three investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, Heron Therapeutics has a consensus rating of “Hold” and an average target price of $4.50.

Heron Therapeutics Profile

Heron Therapeutics, Inc, a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration.